4th Quarter - Report

340B HEALTH for 340B HEALTH

Firm
Client
Income
—
Expenses
$259,229
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 133: Consolidated Appropriations Act, 2021; H.R. 4538, Closing Loopholes for Orphan Drug Act; S. 4160, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R. 7838, To provide for certain temporary waivers with respect to the 340B drug discount program due to the COVID-19 public health emergency, and for other purposes; S.4796, Fair Care Act of 2020; H.R.8527, Fair Care Act of 2020

LobbyistCovered position, as disclosed
ELISE CRANSTON —
KATHRYN DIBITETTO —
GREG DOGGETT —
KATE ILAHI —
AMANDA SELLERS SMITH —
MAUREEN TESTONI —

Contacted: Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 4796 (116th), H.R. 133 (116th), S. 4160 (116th), H.R. 7838 (116th), H.R. 8527 (116th), H.R. 4538 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.